Brief: Zentalis Pharmaceuticals Says Median Overall Survival Of 15.8 Months With Azenosertib In Cyclin E1-Positive Proc
Sun 23:11
BRIEF-Zentalis Pharmaceuticals Says Median Overall Survival Of 15.8 Months With Azenosertib In Cyclin E1-Positive Proc Oct 18 (Reuters) - Zentalis Pharmaceuticals, Inc. ZNTL.O:
ZENTALIS PHARMACEUTICALS ANNOUNCES FIRST OVERALL SURVIVAL DATA FOR AZENOSERTIB FROM DENALI PART 1B PUBLISHED IN ESMO CONGRESS 2026 ABSTRACT
ZENTALIS PHARMACEUTICALS - MEDIAN OVERALL SURVIVAL OF 15.8 MONTHS WITH AZENOSERTIB IN CYCLIN E1-POSITIVE PROC
Source text: ID:nGNXHSp1m
Further company coverage: ZNTL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Zentalis Pharmaceuticals
See all newsBrief: Zentalis Pharmaceuticals Says Median Overall Survival Of 15.8 Months With Azenosertib In Cyclin E1-Positive Proc
Brief: Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
U.S. STOCKS ON THE MOVE-Sun Communities, Cisco Systems, Paysafe
U.S. STOCKS ON THE MOVE-Fox, Sun Communities, Reddit, drone firms
U.S. STOCKS ON THE MOVE-Boost Run, Nektar Therapeutics, Swarmer